To open up the markets of Great Britain, Ireland, and subsequently the USA for the tinnitus therapy device tinniwell, Resaphene UK Ltd. has been established in London. Additionally, this subsidiary facilitates investment in the company by local venture capital and private equity firms, as these investments can be written off for tax purposes.